glp-1 agonist and gastroparesis Receptor Agonists in Gastrointestinal Practices: Enhancing Both Procedural Patient-Related Outcomes | SN Comprehensive Clinical Medicine GI Adverse Effects of Glucagon-Like
Description
Whether you have just started us
Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity
By 2030, the global prevalence of obesity is expected to reach one billion
Taking Wegovy or Ozempic
Jacqueline Cooper, IBCLC
